This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
Paige McDonald, Ph.D., Phone: 301-435-5037, Email: firstname.lastname@example.org
The potent effects of neuroimmune molecules in the brain are mediated through multiple signaling pathways. However, details regarding the extent, routes, or mechanisms whereby immune signaling affects the brain in either normal conditions or during immune challenge and inflammation are largely unexplored. The purpose of this FOA is to identify research opportunities that may help to bridge the gap in understanding how immune cells and their mediators affect brain development, function and behaviors related to cognition and mood.
See full description in NIH Guide:PA-06-533
4 different contacts for the different ICs
This FOA is intended to stimulate the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. The widespread availability and use of these radioligands are expected to: 1) accelerate research on identifying and characterizing the neural circuits and pathways implicated in the pathophysiology of brain disorders (especially mental and behavioral disorders, substance abuse, neurodegenerative disorders, and pediatric brain disorders) and brain changes with age, and 2) facilitate the identification of new therapeutic targets and the development of new compounds as potential therapeutic agents. Research partnerships among investigators in both academia and pharmaceutical and biotechnology industries are encouraged to more rapidly develop PET and SPECT radiotracers and apply neuroimaging in drug discovery, biomarker development//qualification, and pathophysiological studies.
Molecular targets for which radioligands (agonist and antagonist ) are needed include, but are not limited to, the following. Please contact program staff to determine program priorities and molecular targets of interest to specific NIH Institutes or refer to the Internet addresses listed above for each of the participating NIH Institutes.
David J. Eckstein, Ph.D. (NCI), Phone: 301-496-8580, Email: Eckstein@mail.nih.gov
The Mentored Clinical Scientist Research Career Development Award (K08) represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (K23).
An award is for a period of 3 to 5 years and provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (http://grants.nih.gov/grants/guide/contacts/pa-06-512_contacts.htm).
See full description in NIH Guide:PAR-06-512
This funding opportunity announcement (FOA) is aimed at enhancing nanoscience and nanotechnology research approaches that have the potential to make valuable contributions to biology and medicine. The purpose of this initiative is to stimulate cross-cutting, integrative research in these fields of science and technology. In particular, this initiative invites research on: i) the creation and use of structures, devices and systems that have novel properties and functions because of their small size, that may be used to achieve a fundamental understanding of biological processes and /or contribute to disease detection, therapy, or prevention; ii) conception and fabrication of devices, that will effectively detect and analyze nanoscale entities of relevance to biomedicine; and iii) the study of biological systems at the nanoscale for the explicit purpose of using that information to develop nanotechnologies and nanostructured materials that will in turn benefit biology and medicine. The research projects that will be most responsive to this FOA will require interdisciplinary collaborations among investigators with expertise in a range of disciplines, including but not limited to engineering, physics, chemistry, cellular and molecular biology, materials and computer science. Applications submitted in response to this PA may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.
See full description in NIH Guide:PAR-06-475
The CAP consists of training workshops, individual mentoring and consulting sessions, and it culminates with an opportunity for companies to present their business opportunities to potential investors and strategic partners at the NIH Life Sciences Showcase. Participation is free; however, selected participants are responsible for their travel expenses to attend two required workshops and the optional showcase. Detailed program information, eligibility requirements, and application instructions are available at http://www.larta.org/nihcap/NIHCAP-ProgramDescription.pdf. The deadline for submitting an application is July 31, 2006. Approximately 125 companies will be selected to participate in this year's NIH CAP and will be notified by August 14, 2006.
See full description in NIH Guide:NOT-OD-06-08
Jeff Schloss, Ph. D., NHGRI, Phone: 301-435-5538, Email: email@example.com
See full description in NIH Guide:NIH PAR-06-475
The primary objective of this program announcement is to encourage basic, applied, and translational bioengineering research that could make a significant contribution to improving human health. Bioengineering integrates physical, engineering, and computational science principles for the study of biology, medicine, behavior, or health. It advances fundamental concepts, creates knowledge from the molecular to the organ systems level, and develops innovative biologicals, materials, processes, implants, devices, and informatics approaches for the prevention, diagnosis, and treatment of disease, for patient rehabilitation, and for improving health. Some BRP projects may propose research that could lead to a novel device as a product. Partnership with companies that have relevant expertise or that may eventually be involved in commercialization is appropriate under the BRP program.
A second objective is to encourage collaborations and partnerships among the allied quantitative and biomedical disciplines. A BRP must bring together the necessary physical, engineering, and computational science expertise with biological or clinical expertise and resources to address a significant area of bioengineering research within the mission of the NIH. In addition to the benefits to be derived from the research, the collaborations and partnerships can create opportunities for trans-disciplinary communication and training for a new generation of scientists capable of interacting across traditional technical boundaries.
Applications for a BRP award should focus bioengineering research on an area of basic, applied, translational, behavioral, or clinical research that supports the missions of the participating NIH institutes and centers and where progress is likely to make a significant contribution to improving human health. Some NIH institutes and centers have indicated that they will only consider BRP applications in specific focus areas or use different budget caps. These institutes and focus areas are available at http://www.becon.nih.gov/becon_brpareas.htm.
See full description in NIH Guide:PAR-06-459
Dr. David J. Eckstein, NCI, Phone: 301-496-8580, Email: firstname.lastname@example.org
The major objective of the NCI Transition Career Development Award program is two-fold: (i) to provide a mechanism for stabilizing the career tracks of the most promising of investigators while they are establishing their first independent research programs and (ii) to create equal access to extramural career development opportunities to postdoctoral scientists in basic human cancer research working as Federal employees.
See full description in NIH Guide:PAR-06-455
The objective of the NRSA program is to provide predoctoral and postdoctoral research training opportunities for individuals interested in pursuing research careers in biomedical, behavioral and clinical research. Each NIH Institute and Center has a unique scientific purview and different program goals and initiatives that evolve over time. It is therefore critical that all applicants consult with the scientific/research contact at the relevant NIH Institute or Center for current information about program priorities and policies before preparing an application. This action is of utmost importance because applications with marginal or no relevance to the NIH awarding components participating in this funding opportunity announcement will not be accepted for review or considered for funding.
See full description in NIH Guide:PA-06-468
Dr. Roy Wu, NCI, Phone: 301-496-8866, Email: email@example.com
This FOA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and an accelerated peer review with the goal of issuing new awards within 6 months of application receipt. Inclusion of the complete clinical protocol within the grant application is intended to simplify the application process by eliminating the need to duplicate protocol details in the Research Plan section and to insure proper peer review of the application. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy, and rapid development and application of novel clinical cancer therapies, including image-guided therapeutic procedures.
See full description in NIH Guide:PAR-06-451